



LKT Laboratories, Inc.

Vemurafenib

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID V1668

CAS No. 918504-65-1

Chemical Name N-(3-(5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonamide

Synonym PLX-4032, RG7204, RO5185426, Zelboraf

Formula C₂₃H₁₈ClF₂N₃O₃S

Formula Wt. 489.92

Melting Point


Purity ≥98%

Solubility Soluble in DMSO at 100 mg/mL;
very poorly soluble in ethanol;
very poorly soluble in water;
maximum solubility in plain
water is estimated to be about

Store Temp -20°C

Ship Temp Ambient

Description Vemurafenib is a first generation selective B-Raf inhibitor that has been approved for clinical use in treating unresectable or metastatic melanoma; it exhibits anticancer chemotherapeutic activity. Vemurafenib binds the ATP-binding domain of mutant (V600E) B-Raf, present in many cancer subtypes, to inhibit downstream MEK and ERK signaling. This compound inhibits MAPK signaling and cell cycle progression in cells expressing mutant (V600E) B-Raf, but may increase MAPK signaling in cells expressing WT B-Raf. Subjects undergoing treatment with Vemurafenib have potential to develop verrucal keratosis and cutaneous squamous cell carcinoma as side effects. Vemurafenib is currently under examination as a potential treatment against tumors expressing H-Ras mutations as well.



Pricing and Availability

Bulk quantities available upon request

Product ID	Size
V1668	10 mg
V1668	25 mg

References Anforth R, Blumetti TC, Clements A, et al. Systemic Retinoids for the Chemoprevention of Cutaneous Squamous Cell Carcinoma and Verrucal Keratosis in a Cohort of Patients on BRAF inhibitors. *Br J Dermatol.* 2013 Jul 20. PMID: 23870055.

Beck D, Niessner H, Smalley KS, et al. Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells. *Sci Signal.* 2013 Jan 29;6(260):ra7. PMID: 23362240.

Huang T, Karsy M, Zhuge J, et al. B-Raf and the inhibitors: from bench to bedside. *J Hematol Oncol.* 2013 Apr 25;6:30. PMID: 23617957.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.